Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
23 07 2019
Historique:
received: 11 03 2019
revised: 23 04 2019
accepted: 29 04 2019
entrez: 20 7 2019
pubmed: 20 7 2019
medline: 22 5 2020
Statut: ppublish

Résumé

Fulminant myocarditis (FM) is a form of acute myocarditis characterized by severe left ventricular systolic dysfunction requiring inotropes and/or mechanical circulatory support. A single-center study found that a patient with FM had better outcomes than those with acute nonfulminant myocarditis (NFM) presenting with left ventricular systolic dysfunction, but otherwise hemodynamically stable. This was recently challenged, so disagreement still exists. This study sought to provide additional evidence on the outcome of FM and to ascertain whether patient stratification based on the main histologic subtypes can provide additional prognostic information. A total of 220 patients (median age 42 years, 46.3% female) with histologically proven acute myocarditis (onset of symptoms <30 days) all presenting with left ventricular systolic dysfunction were included in a retrospective, international registry comprising 16 tertiary hospitals in the United States, Europe, and Japan. The main endpoint was the occurrence of cardiac death or heart transplantation within 60 days from admission and at long-term follow-up. Patients with FM (n = 165) had significantly higher rates of cardiac death and heart transplantation compared with those with NFM (n = 55), both at 60 days (28.0% vs. 1.8%, p = 0.0001) and at 7-year follow-up (47.7% vs. 10.4%, p < 0.0001). Using Cox multivariate analysis, the histologic subtype emerged as a further variable affecting the outcome in FM patients, with giant cell myocarditis having a significantly worse prognosis compared with eosinophilic and lymphocytic myocarditis. In a subanalysis including only adults with lymphocytic myocarditis, the main endpoints occurred more frequently in FM compared with in NFM both at 60 days (19.5% vs. 0%, p = 0.005) and at 7-year follow up (41.4% vs. 3.1%, p = 0.0004). This international registry confirms that patients with FM have higher rates of cardiac death and heart transplantation both in the short- and long-term compared with patients with NFM. Furthermore, we provide evidence that the histologic subtype of FM carries independent prognostic value, highlighting the need for timely endomyocardial biopsy in this condition.

Sections du résumé

BACKGROUND
Fulminant myocarditis (FM) is a form of acute myocarditis characterized by severe left ventricular systolic dysfunction requiring inotropes and/or mechanical circulatory support. A single-center study found that a patient with FM had better outcomes than those with acute nonfulminant myocarditis (NFM) presenting with left ventricular systolic dysfunction, but otherwise hemodynamically stable. This was recently challenged, so disagreement still exists.
OBJECTIVES
This study sought to provide additional evidence on the outcome of FM and to ascertain whether patient stratification based on the main histologic subtypes can provide additional prognostic information.
METHODS
A total of 220 patients (median age 42 years, 46.3% female) with histologically proven acute myocarditis (onset of symptoms <30 days) all presenting with left ventricular systolic dysfunction were included in a retrospective, international registry comprising 16 tertiary hospitals in the United States, Europe, and Japan. The main endpoint was the occurrence of cardiac death or heart transplantation within 60 days from admission and at long-term follow-up.
RESULTS
Patients with FM (n = 165) had significantly higher rates of cardiac death and heart transplantation compared with those with NFM (n = 55), both at 60 days (28.0% vs. 1.8%, p = 0.0001) and at 7-year follow-up (47.7% vs. 10.4%, p < 0.0001). Using Cox multivariate analysis, the histologic subtype emerged as a further variable affecting the outcome in FM patients, with giant cell myocarditis having a significantly worse prognosis compared with eosinophilic and lymphocytic myocarditis. In a subanalysis including only adults with lymphocytic myocarditis, the main endpoints occurred more frequently in FM compared with in NFM both at 60 days (19.5% vs. 0%, p = 0.005) and at 7-year follow up (41.4% vs. 3.1%, p = 0.0004).
CONCLUSIONS
This international registry confirms that patients with FM have higher rates of cardiac death and heart transplantation both in the short- and long-term compared with patients with NFM. Furthermore, we provide evidence that the histologic subtype of FM carries independent prognostic value, highlighting the need for timely endomyocardial biopsy in this condition.

Identifiants

pubmed: 31319912
pii: S0735-1097(19)35290-8
doi: 10.1016/j.jacc.2019.04.063
pii:
doi:

Types de publication

Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

299-311

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Enrico Ammirati (E)

De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy. Electronic address: enrico.ammirati@ospedaleniguarda.it.

Giacomo Veronese (G)

De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy; Department of Health Sciences, University of Milano-Bicocca, Monza, Italy.

Michela Brambatti (M)

Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, California.

Marco Merlo (M)

Cardiothoracic Department, Azienda Sanitaria Universitaria Integrata (ASUITS), University of Trieste, Trieste, Italy.

Manlio Cipriani (M)

De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy.

Luciano Potena (L)

Academic Hospital S. Orsola-Malpighi, Bologna, Italy.

Paola Sormani (P)

De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy.

Tatsuo Aoki (T)

Tohoku University Graduate School of Medicine, Sendai, Japan.

Koichiro Sugimura (K)

Tohoku University Graduate School of Medicine, Sendai, Japan.

Akinori Sawamura (A)

Nagoya University Graduate School of Medicine, Nagoya, Japan.

Takahiro Okumura (T)

Nagoya University Graduate School of Medicine, Nagoya, Japan.

Sean Pinney (S)

Icahn School of Medicine at Mount Sinai, New York, New York.

Kimberly Hong (K)

Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, California.

Palak Shah (P)

Inova Heart and Vascular Institute, Falls Church, Virginia.

Öscar Braun (Ö)

Department of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.

Caroline M Van de Heyning (CM)

Department of Cardiology, Antwerp University Hospital, Edegem, Belgium.

Santiago Montero (S)

Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute IIB Sant Pau, CIBER-CV, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Medical Intensive Care Unit, Paris Cedex 13, France.

Duccio Petrella (D)

De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy.

Florent Huang (F)

Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Medical Intensive Care Unit, Paris Cedex 13, France.

Matthieu Schmidt (M)

Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Medical Intensive Care Unit, Paris Cedex 13, France.

Claudia Raineri (C)

Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.

Anuradha Lala (A)

Icahn School of Medicine at Mount Sinai, New York, New York.

Marisa Varrenti (M)

De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy; Department of Health Sciences, University of Milano-Bicocca, Monza, Italy.

Alberto Foà (A)

Academic Hospital S. Orsola-Malpighi, Bologna, Italy.

Ornella Leone (O)

Academic Hospital S. Orsola-Malpighi, Bologna, Italy.

Piero Gentile (P)

Cardiothoracic Department, Azienda Sanitaria Universitaria Integrata (ASUITS), University of Trieste, Trieste, Italy.

Jessica Artico (J)

Cardiothoracic Department, Azienda Sanitaria Universitaria Integrata (ASUITS), University of Trieste, Trieste, Italy.

Valentina Agostini (V)

Academic Hospital S. Orsola-Malpighi, Bologna, Italy.

Rajiv Patel (R)

Inova Heart and Vascular Institute, Falls Church, Virginia.

Andrea Garascia (A)

De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy.

Emeline M Van Craenenbroeck (EM)

Department of Cardiology, Antwerp University Hospital, Edegem, Belgium.

Kaoru Hirose (K)

Kokura Memorial Hospital, Kitakyushu, Japan.

Akihiro Isotani (A)

Kokura Memorial Hospital, Kitakyushu, Japan.

Toyoaki Murohara (T)

Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yoh Arita (Y)

Japan Community Healthcare Organization, Osaka Hospital, Osaka, Japan.

Alessandro Sionis (A)

Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute IIB Sant Pau, CIBER-CV, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

Enrico Fabris (E)

Cardiothoracic Department, Azienda Sanitaria Universitaria Integrata (ASUITS), University of Trieste, Trieste, Italy.

Sherin Hashem (S)

Department of Pathology, University of California, San Diego, La Jolla, California.

Victor Garcia-Hernando (V)

Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute IIB Sant Pau, CIBER-CV, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

Fabrizio Oliva (F)

De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy.

Barry Greenberg (B)

Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, California.

Hiroaki Shimokawa (H)

Tohoku University Graduate School of Medicine, Sendai, Japan.

Gianfranco Sinagra (G)

Cardiothoracic Department, Azienda Sanitaria Universitaria Integrata (ASUITS), University of Trieste, Trieste, Italy.

Eric D Adler (ED)

Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, California. Electronic address: eradler@ucsd.edu.

Maria Frigerio (M)

De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy.

Paolo G Camici (PG)

Vita Salute University and San Raffaele Hospital, Milano, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH